TRIAL/PROGRAM STATUSES - 2nd February 2022

Update Provided on Precision Promise Trial of SM-88 in Metastatic Pancreatic Cancer

"Given pancreatic cancer's high mortality rate, we wanted to make a difference in the lives of these patients. Our team understood that many efforts before us have failed, but based on SM-88's prior activity and safety profile, we were hopeful we could provide an effective new option for those fighting against this devastating disease," said Richie Cunningham, Chief Executive Officer of TYME. "I want to express my sincerest appreciation to the patients, their loved ones, the researchers, and the principal investigators involved in this trial, as well as thank PanCAN and Precision Promise for their passionate dedication to exploring new treatment options for pancreatic cancer patients."

First Patient Dosed in Randomised Ph 2 Clinical Trial of MTL-CEBPA in Patients with Advanced Liver Cancer

Robert Habib, CEO of MiNA Therapeutics, commented: "We are very excited to dose our first patient in the OUTREACH-2 study, which is the first Phase 2 clinical trial of a RNAa therapeutic. MTL-CEBPA has demonstrated its potential to make tumours more susceptible to established anti-cancer therapies, which can significantly improve treatment outcomes for patients. We look forward to building on data from our successful Phase 1b study of the sorafenib combination and to developing MTL-CEBPA more broadly for the benefit of patients."

Ph 2 ASPIRE trial of Nab-Paclitaxel + Gemcitabine +/- SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma initiated

"Pancreatic cancer is one of the most common causes of cancer deaths in the United States and represents a significant unmet medical need, as is underscored by SBP-101's Fast Track and Orphan Drug designations," said Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer. "We are enthusiastic about having initiated the ASPIRE global randomized Phase 2 trial. Given the rigor of the trial design, we expect the resulting data to support our registration effort."

Ph 2 Studies Patient Enrollment for OBI-999 and OBI-3424 Announced

OBI's Chairman and Chief Executive Officer, Michael Chang, PhD, noted "OBI Pharma strives to develop novel therapeutics for cancer patients worldwide. Based upon the impressive Phase 1 safety study and preclinical data of OBI-999 and OBI-3424, we are excited to commence our Phase 2 efficacy and safety study in patients with high Globo H or AKR1C3 antigen expression in solid tumors. We would like to thank the commitment of our international investigators to bring these 1st-in-class cancer therapeutic products to potential patients in our ongoing study."

First Patient dosed in Ph 1b/2a Trial of BM4003 in combination therapy with toripalimab

- Harbour BioMed announced that it has successfully completed the dosing of first patient in phase Ib/IIa trial at the stage of dose expansion of its anti-CTLA-4 antibody (HBM4003) in combination therapy with toripalimab (anti-PD-1 antibody) for patients suffering from advanced melanoma and other solid tumors.

- HBM4003 showed its good safety profile and strong efficacy on its monotherapy study of phase I trial.
- HBM is pushing forward the studies of this product in combination therapy as treatment for multiple solid tumors, including melanoma, NSCLC, HCC, NET/NEC.